<DOC>
	<DOCNO>NCT00287885</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Docetaxel may also stop growth tumor cell block blood flow tumor . Giving daily dos docetaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel treat patient refractory recurrent advance gynecologic cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Refractory Recurrent Advanced Gynecologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose metronomic docetaxel patient progressive recurrent gynecologic cancer . Secondary - Determine response rate patient treat drug . - Determine pharmacokinetics associated drug patient . OUTLINE : This dose-escalation study . Patients receive docetaxel intravenously ( IV ) 1-2 minute daily 6 month absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must histologically confirm advanced , refractory gynecologic cancer . Patients must receive prior chemotherapy , must residual recurrent disease initial therapy subsequent therapy . Patients must least one site bidimensional measurable disease define section 9 must evaluable radiographically nonmeasurable disease associate CA125 &gt; 50 units/ml two measurement least one week apart . Baseline measurement CA125 must obtain patient within four week registration . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Patients must receive hormonal immunologic therapy 2 week cytotoxic chemotherapy radiation therapy 4 week ( nitrosoureas mitomycin C require 6 week ) prior registration . Patients may history prior malignancy past 5 year nonmelanoma skin cancer situ carcinoma cervix . Patients must document adequate organ function within 4 week registration define : Marrow : WBC ≥ 3000/mm3 , ANC ≥ 1500/mm3 , Hgb ≥ 8.0 g/dl , platelet ≥ 100,000/mm3 Hepatic : Total Bilirubin ≤ ULN , SGOT SGPT Alkaline Phosphatase must within range allow eligibility , table SGOT SGPT : Meets 1 follow criterion : Alkaline phosphatase ( AP ) normal AND SGOT SGPT normal AP ≤ 5 time ULN AND SGOT SGPT normal AP normal AND SGOT SGPT ≤ 5 time ULN AP ≤ 2.5 ULN AND SGOT SGPT ≤ 1.5 time ULN Renal : BUN ≤ 30 mg % , creatinine ≤ 1.5 mg % Age ≥ 18 year Pregnant lactating . The agent use study may teratogenic fetus information excretion agent breast milk . Patients reproductive potential must use effective birth control , preferably barrier method . Prior history myocardial infarction , congestive heart failure significant ischemic valvular heart disease . Patients know brain metastasis eligible . Peripheral neuropathy must ≤ grade 2 . Patients history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 must exclude . Patient must give write informed consent indicate investigational nature treatment potential risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>stage III vulvar cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>stage IV vulvar cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>